bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 1 from Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells
Authors: Schreibelt Gerty , Bol Kalijn F. , Westdorp Harm , Wimmers Florian , Aarntzen Erik H.J.G. , Duiveman-de Boer Tjitske , van de Rakt Mandy W.M.M. , Scharenborg Nicole M. , de Boer Annemiek J. , Pots Jeanette M. , Olde Nordkamp Michel A.M. , van Oorschot Tom G.M. , Tel Jurjen , Winkels Gregor , Petry Katja , Blokx Willeke A.M. , van Rossum Michelle M. , Welzen Marieke E.B. , Mus Roel D.M. , Croockewit Sandra A.J. , Koornstra Rutger H.T. , Jacobs Joannes F.M. , Kelderman Sander , Blank Christian U. , Gerritsen Winald R. , Punt Cornelis J.A. , Figdor Carl G. , de Vries I. Jolanda M.
Published: April 2023

Supplementary Figure 1. Schematic overview of the 44 h mDC vaccine preparation cycle and vaccination strategy.
Supplementary Figure S7 from Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer
Authors: Kageyama Shinichi , Ikeda Hiroaki , Miyahara Yoshihiro , Imai Naoko , Ishihara Mikiya , Saito Kanako , Sugino Sahoko , Ueda Shugo , Ishikawa Takeshi , Kokura Satoshi , Naota Hiroaki , Ohishi Kohshi , Shiraishi Taizo , Inoue Naoki , Tanabe Masashige , Kidokoro Tomohide , Yoshioka Hirofumi , Tomura Daisuke , Nukaya Ikuei , Mineno Junichi , Takesako Kazutoh , Katayama Naoyuki , Shiku Hiroshi
Published: April 2023

CT and PET scan images from TCR-MA-213.
Supplementary Figure S6 from Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer
Authors: Kageyama Shinichi , Ikeda Hiroaki , Miyahara Yoshihiro , Imai Naoko , Ishihara Mikiya , Saito Kanako , Sugino Sahoko , Ueda Shugo , Ishikawa Takeshi , Kokura Satoshi , Naota Hiroaki , Ohishi Kohshi , Shiraishi Taizo , Inoue Naoki , Tanabe Masashige , Kidokoro Tomohide , Yoshioka Hirofumi , Tomura Daisuke , Nukaya Ikuei , Mineno Junichi , Takesako Kazutoh , Katayama Naoyuki , Shiku Hiroshi
Published: April 2023

Disease progression and overall survival of 10 patients who received transfer of TCR-transduced lymphocytes.
Supplementary Figure S3 from Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer
Authors: Kageyama Shinichi , Ikeda Hiroaki , Miyahara Yoshihiro , Imai Naoko , Ishihara Mikiya , Saito Kanako , Sugino Sahoko , Ueda Shugo , Ishikawa Takeshi , Kokura Satoshi , Naota Hiroaki , Ohishi Kohshi , Shiraishi Taizo , Inoue Naoki , Tanabe Masashige , Kidokoro Tomohide , Yoshioka Hirofumi , Tomura Daisuke , Nukaya Ikuei , Mineno Junichi , Takesako Kazutoh , Katayama Naoyuki , Shiku Hiroshi
Published: April 2023

Tetramer analysis of the TCR-geneâˆ’transduced T cells at pre-infusion.
Supplementary Fig. S3 from Genetic Evolution of T-cell Resistance in the Course of Melanoma Progression
Authors: Sucker Antje , Zhao Fang , Real Birgit , Heeke Christina , Bielefeld Nicola , Maβen Stefan , Horn Susanne , Moll Iris , Maltaner Raffaela , Horn Peter A. , Schilling Bastian , Sabbatino Francesco , Lennerz Volker , Kloor Matthias , Ferrone Soldano , Schadendorf Dirk , Falk Christine S. , Griewank Klaus , Paschen Annette
Published: April 2023

Supplementary Fig. S3. A, B, analysis of the T cell-stimulatory capacity of the different Ma-Mel-48 tumor cell lines. In autologous mixed lymphocyte-tumor cultures (MLTC) isolated CD8+ T cells were stimulated twice with Ma-Mel-48a (MLTC-48a; A) or Ma-Mel-48b (MLTC-48b; B) cells and subsequently analysed for their response towards different target cells. A, T-cell activation was determined by IFN-γ ELISPOT assay. One representative of 2 independent experiments is depicted. B, T-cell activation was measured by intracellular staining for TNF-α. The mean %TNF-α+CD8+ T cells within CD8+CD3+ T cells of three independent experiments is presented. A, B, where indicated anti-PD-L1 mAb was added to block inhibitory signaling to the T cells. Control cells were incubated with mouse IgG1 (mIgG).
Supplementary Fig. S2 from Genetic Evolution of T-cell Resistance in the Course of Melanoma Progression
Authors: Sucker Antje , Zhao Fang , Real Birgit , Heeke Christina , Bielefeld Nicola , Maβen Stefan , Horn Susanne , Moll Iris , Maltaner Raffaela , Horn Peter A. , Schilling Bastian , Sabbatino Francesco , Lennerz Volker , Kloor Matthias , Ferrone Soldano , Schadendorf Dirk , Falk Christine S. , Griewank Klaus , Paschen Annette
Published: April 2023

Supplementary Fig. S2. The different Ma-Mel-48 cell lines were treated with IFN-γ (500 U/ml) for 48 h, controls were left untreated. Cells were stained with mAb L243 and mAb W6/32 for detection of HLA-DR and HLA class I antigen expression, respectively. Representative histograms from one of three independent experiments are depicted.
Supplementary Figure S1 from Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer
Authors: Kageyama Shinichi , Ikeda Hiroaki , Miyahara Yoshihiro , Imai Naoko , Ishihara Mikiya , Saito Kanako , Sugino Sahoko , Ueda Shugo , Ishikawa Takeshi , Kokura Satoshi , Naota Hiroaki , Ohishi Kohshi , Shiraishi Taizo , Inoue Naoki , Tanabe Masashige , Kidokoro Tomohide , Yoshioka Hirofumi , Tomura Daisuke , Nukaya Ikuei , Mineno Junichi , Takesako Kazutoh , Katayama Naoyuki , Shiku Hiroshi
Published: April 2023

Equivalent amplification of human IFN-gamma gene and the retrovirus transgene by the quantitative PCR.
Supplementary Figure SF1 from Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome
Authors: GuhaThakurta Debraj , Sheikh Nadeem A. , Fan Li-Qun , Kandadi Harini , Meagher T. Craig , Hall Simon J. , Kantoff Philip W. , Higano Celestia S. , Small Eric J. , Gardner Thomas A. , Bailey Kate , Vu Tuyen , DeVries Todd , Whitmore James B. , Frohlich Mark W. , Trager James B. , Drake Charles G.
Published: April 2023

Supplementary Figure SF1. Schematic of sipuleucel-T treatment doses (infusions) and serum collection time points in IMPACT and ProACT.
Supplemental Figures 1-5, Tables 4-6 from Integrative Protein-Based Prognostic Model for Early-Stage Endometrioid Endometrial Cancer
Authors: Yang Ji-Yeon , Werner Henrica M.J. , Li Jie , Westin Shannon N. , Lu Yiling , Halle Mari K. , Trovik Jone , Salvesen Helga B. , Mills Gordon B. , Liang Han
Published: April 2023

Supplemental Figures 1-5, Tables 4-6. Supplemental Figure 1. Kaplan-Meier curves comparing overall survivals for the training and validation cohorts Supplemental Figure 2. Kaplan-Meier curves for the late-stage EEC samples (FIGO 2009 stages III & IV) in the training and validation cohorts. Supplemental Figure 3. Plots in the first column display the distributions of risk scores of earlystage EEC samples in the training and validation cohorts. Supplemental Figure 4. Kaplan-Meier curves for the early-stage and late-stage EEC samples in the training and validation cohorts. Supplemental Figure 5. Kaplan-Meier curves for the late-stage EEC samples (stages III & IV) in the training and validation cohorts. Risk scores for patients were computed using the late-stage integrative model. Supplemental Table 4. Markers comprising the integrative model for the patients with early-stage EEC Supplemental Table 5. Markers included the integrative model for patients with late-stage EEC Supplemental Table 6. Univariate and multivariate Cox's proportional hazards model analysis for the late-stage EEC samples
Table S1 from The Impact of Clone Size on the Prognostic Value of Chromosome Aberrations by Fluorescence In Situ Hybridization in Multiple Myeloma
Authors: An Gang , Li Zengjun , Tai Yu-Tzu , Acharya Chirag , Li Qian , Qin Xiaoqi , Yi Shuhua , Xu Yan , Feng Xiaoyan , Li Chengwen , Zhao Jiawei , Shi Lihui , Zang Meirong , Deng Shuhui , Sui Weiwei , Hao Mu , Zou Dehui , Zhao Yaozhong , Qi Junyuan , Cheng Tao , Ru Kun , Wang Jianxiang , Anderson Kenneth C , Qiu Lugui
Published: April 2023

Table S1. The distribution of cytogenetics by probes in positive group.
Figure S1 from The Impact of Clone Size on the Prognostic Value of Chromosome Aberrations by Fluorescence In Situ Hybridization in Multiple Myeloma
Authors: An Gang , Li Zengjun , Tai Yu-Tzu , Acharya Chirag , Li Qian , Qin Xiaoqi , Yi Shuhua , Xu Yan , Feng Xiaoyan , Li Chengwen , Zhao Jiawei , Shi Lihui , Zang Meirong , Deng Shuhui , Sui Weiwei , Hao Mu , Zou Dehui , Zhao Yaozhong , Qi Junyuan , Cheng Tao , Ru Kun , Wang Jianxiang , Anderson Kenneth C , Qiu Lugui
Published: April 2023

Figure S1. ROC curve for the relation of cytogenetic abnormalities and progression or survival in MM patients.
Supplementary Table 1 from The New Antitumor Drug ABTL0812 Inhibits the Akt/mTORC1 Axis by Upregulating Tribbles-3 Pseudokinase
Authors: Erazo Tatiana , Lorente Mar , López-Plana Anna , Muñoz-Guardiola Pau , Fernández-Nogueira Patricia , García-Martínez José A. , Bragado Paloma , Fuster Gemma , Salazar María , Espadaler Jordi , Hernández-Losa Javier , Bayascas Jose Ramon , Cortal Marc , Vidal Laura , Gascón Pedro , Gómez-Ferreria Mariana , Alfón José , Velasco Guillermo , Domènech Carles , Lizcano Jose M.
Published: April 2023

List of antibodies used in this work
Supplementary Figure S5 - S6 from Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins
Authors: Tanaka Noriaki , Patel Ameeta A. , Wang Jiping , Frederick Mitchell J. , Kalu Nene N. , Zhao Mei , Fitzgerald Alison L. , Xie Tong-xin , Silver Natalie L. , Caulin Carlos , Zhou Ge , Skinner Heath D. , Johnson Faye M. , Myers Jeffrey N. , Osman Abdullah A.
Published: April 2023

Supplementary Figure S5. Downregulation of MCl-1, XIAP and their cleavage by AZD-1775 in HPV+ HNSCC cells are caspase-dependent;and Supplementary Figure S6. mRNA levels of MCl-1, XIAP and stable forced expression of MCl-1 in HPV+ HNSCC cells.
Supplementary Figure S3 - S4 from Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins
Authors: Tanaka Noriaki , Patel Ameeta A. , Wang Jiping , Frederick Mitchell J. , Kalu Nene N. , Zhao Mei , Fitzgerald Alison L. , Xie Tong-xin , Silver Natalie L. , Caulin Carlos , Zhou Ge , Skinner Heath D. , Johnson Faye M. , Myers Jeffrey N. , Osman Abdullah A.
Published: April 2023

Supplementary Figure S3. Percentage of cell-cycle distribution in HPV+ HNSCC cells; and Supplementary Figure S4. AZD-1775 induces caspase-dependent apoptosis in HPV+ but not the HPV- HNSCC cells.
Supplementary Materials and Methods from Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients—Report of a Phase I/IIa Clinical Trial
Authors: Legat Amandine , Maby-El Hajjami Hélène , Baumgaertner Petra , Cagnon Laurène , Abed Maillard Samia , Geldhof Christine , Iancu Emanuela M. , Lebon Luc , Guillaume Philippe , Dojcinovic Danijel , Michielin Olivier , Romano Emanuela , Berthod Grégoire , Rimoldi Donata , Triebel Frédéric , Luescher Immanuel , Rufer Nathalie , Speiser Daniel E.
Published: April 2023

More detailed materials and methods information
Supplementary Figure 4 from Loss of SMAD4 Promotes Colorectal Cancer Progression by Accumulation of Myeloid-Derived Suppressor Cells through the CCL15–CCR1 Chemokine Axis
Authors: Inamoto Susumu , Itatani Yoshiro , Yamamoto Takamasa , Minamiguchi Sachiko , Hirai Hideyo , Iwamoto Masayoshi , Hasegawa Suguru , Taketo Makoto Mark , Sakai Yoshiharu , Kawada Kenji
Published: April 2023

CCR3+ cells accumulation in primary CRC.
Supplementary Figure Legends from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival
Authors: Cornell Liam , Munck Joanne M. , Alsinet Clara , Villanueva Augusto , Ogle Laura , Willoughby Catherine E. , Televantou Despina , Thomas Huw D. , Jackson Jennifer , Burt Alastair D. , Newell David , Rose John , Manas Derek M. , Shapiro Geoffrey I. , Curtin Nicola J. , Reeves Helen L.
Published: April 2023

Supplementary Figure Legends
Supplemental material and methods from Loss of SMAD4 Promotes Colorectal Cancer Progression by Accumulation of Myeloid-Derived Suppressor Cells through the CCL15–CCR1 Chemokine Axis
Authors: Inamoto Susumu , Itatani Yoshiro , Yamamoto Takamasa , Minamiguchi Sachiko , Hirai Hideyo , Iwamoto Masayoshi , Hasegawa Suguru , Taketo Makoto Mark , Sakai Yoshiharu , Kawada Kenji
Published: April 2023

Supplementary material and methods. In vivo xenograft studies, lentiviral transduction, cell viability assay and ELISA.
Supplemental Figure 1 from Loss of SMAD4 Promotes Colorectal Cancer Progression by Accumulation of Myeloid-Derived Suppressor Cells through the CCL15–CCR1 Chemokine Axis
Authors: Inamoto Susumu , Itatani Yoshiro , Yamamoto Takamasa , Minamiguchi Sachiko , Hirai Hideyo , Iwamoto Masayoshi , Hasegawa Suguru , Taketo Makoto Mark , Sakai Yoshiharu , Kawada Kenji
Published: April 2023

A. CCL15 concentration in Colo205 cells. B. Cell proliferation rates of HT29 and Colo205 cells.
Supplementary Figures 1-8 from Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency
Authors: Yen Wan-Ching , Fischer Marcus M. , Axelrod Fumiko , Bond Christopher , Cain Jennifer , Cancilla Belinda , Henner William R. , Meisner Rene , Sato Aaron , Shah Jalpa , Tang Tracy , Wallace Breanna , Wang Min , Zhang Chun , Kapoun Ann M. , Lewicki John , Gurney Austin , Hoey Timothy
Published: April 2023

Figure S1A. Binding affinities of OMP-59R5 to human (h) Notch1-4 receptors; Figure S1B. Alignment of the EGF repeats 10-15 of Notch2 and 9-14 of Notch3 from human (h), cynomolgus monkey (cyno), and mouse (m); Figure S2. Human NOTCH1, NOTCH2 and NOTCH3 gene in patient-derived primary xenograft tumors; Figure S3. Effect of OMP-59R5 on tumor growth of individual animals in OMP-PN8 and OMP-PN17 xenografts (from Figure 2); Figure S4A. Effect of OMP-59R5 on goblet cells; Figure S4B. Effect of OMP-59R5 on teeth in NOD/SCID mice; Figure S5. Effect of OMP-59R5 on (a) gene expression, (b) Human vimentin IHC (c) Western blot of Notch3 transmembrane domain (TM) and Notch3 intracellular domain (ICD) protein levels and (d) Quantitation of Notch1 ICD staining intensity levels in pancreatic xenograft tumors; Figure S6A. Effect of OMP-59R5 in combination with gemcitabine or gemcitabine/nab-paclitaxel in OMP-PN8 xenograft tumors; Figure S6B. Effect of OMP-59R5 in combination with gemcitabine/nab-paclitaxel on body weight change in OMP-PN8 xenograft tumor-bearing NOD/SCID mice (from Figure 4B); Figure S6C. Activity of OMP-59R5 in combination with nab-paclitaxel plus gemcitabine in OMP-PN16; Figure S8A. Perfused vessels are associated with the presence of desmin; Figure S8B. Quantification of perfused blood vessels; Figure S8C. Targeting DLL4/Notch signaling and Notch2/3 signaling has opposite effect on tumor stroma/vasculature; Figure S7A. Anti-tumor effect of OMP-59R5 in SCLC tumors; Figure S7B. Effect of OMP-59R5 on Notch3 ECD and Notch3 ICD expression in UM-PE13 xenograft tumors; Figure S7C. Limiting Dilution Assay
Supplemental Methods from Tyrosine Kinase Inhibition in Leukemia Induces an Altered Metabolic State Sensitive to Mitochondrial Perturbations
Authors: Alvarez-Calderon Francesca , Gregory Mark A. , Pham-Danis Catherine , DeRyckere Deborah , Stevens Brett M. , Zaberezhnyy Vadym , Hill Amanda A. , Gemta Lelisa , Kumar Amit , Kumar Vijay , Wempe Michael F. , Pollyea Daniel A. , Jordan Craig T. , Serkova Natalie J. , Graham Douglas K. , DeGregori James
Published: April 2023

Supplemental Methods. This supplementary file includes additional methods for sample preparation, Seahorse analysis of oxygen consumption rates, reactive oxygen species measurements, flow cytometry analysis, NMR analysis, RT-PCR conditions, quizartinib synthesis information.
Supplementary Figure 1 from MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial
Authors: Weller Michael , Tabatabai Ghazaleh , Kästner Bärbel , Felsberg Jörg , Steinbach Joachim P. , Wick Antje , Schnell Oliver , Hau Peter , Herrlinger Ulrich , Sabel Michael C. , Wirsching Hans-Georg , Ketter Ralf , Bähr Oliver , Platten Michael , Tonn Jörg C. , Schlegel Uwe , Marosi Christine , Goldbrunner Roland , Stupp Roger , Homicsko Krisztian , Pichler Josef , Nikkhah Guido , Meixensberger Jürgen , Vajkoczy Peter , Kollias Spyros , Hüsing Johannes , Reifenberger Guido , Wick Wolfgang
Published: April 2023

Supplementary Figure 1. MMSE assessment at study entry, during treatment, and at follow-up
Supplementary Figure S2 from Integrating RAS Status into Prognostic Signatures for Adenocarcinomas of the Lung
Authors: Starmans Maud HW. , Pintilie Melania , Chan-Seng-Yue Michelle , Moon Nathalie C. , Haider Syed , Nguyen Francis , Lau Suzanne K. , Liu Ni , Kasprzyk Arek , Wouters Bradly G. , Der Sandy D. , Shepherd Frances A. , Jurisica Igor , Penn Linda Z. , Tsao Ming-Sound , Lambin Philippe , Boutros Paul C.
Published: April 2023

Supplementary Figure S2. RAS status influences prognostic performance of the 6-gene signature. Kaplan-Meier survival curves for RASwt (A) and RASmt (B) patients, stratified according to the 6-gene signature.
Supplemental methods, legends, and tables from A miRNA-Based Signature Detected in Primary Melanoma Tissue Predicts Development of Brain Metastasis
Authors: Hanniford Doug , Zhong Judy , Koetz Lisa , Gaziel-Sovran Avital , Lackaye Daniel J. , Shang Shulian , Pavlick Anna , Shapiro Richard , Berman Russell , Darvishian Farbod , Shao Yongzhao , Osman Iman , Hernando Eva
Published: April 2023

Supplemental methods, legends, and tables. This file contains supplemental methods for the sensitivity analyses performed to test the robustness of the miRNA model and RT-qPCR quality control. It also contains four supplemental tables (described below) and supplemental figure legends TableS1 - Hazard ratios of miRNA signature TableS2 - Odds ratios of logistic regression-derived miRNA signature TableS3 - Performance metrics of miRNA signature in each cohort TableS4 - Performance of miRNA signature within individual stages.
Supplemental Figure S7 from The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment
Authors: Meisen W. Hans , Wohleb Eric S. , Jaime-Ramirez Alena Cristina , Bolyard Chelsea , Yoo Ji Young , Russell Luke , Hardcastle Jayson , Dubin Samuel , Muili Kamaldeen , Yu Jianhua , Caligiuri Michael , Godbout Jonathan , Kaur Balveen
Published: April 2023

Supplemental Figure S7. TNFα induces apoptosis in oHSV infected glioma cells.
Supplementary Methods from Dysregulation of miR-212 Promotes Castration Resistance through hnRNPH1-Mediated Regulation of AR and AR-V7: Implications for Racial Disparity of Prostate Cancer
Authors: Yang Yijun , Jia Dingwu , Kim Hogyoung , Abd Elmageed Zakaria Y. , Datta Amrita , Davis Rodney , Srivastav Sudesh , Moroz Krzysztof , Crawford Byron E. , Moparty Krishnarao , Thomas Raju , Hudson Robert S. , Ambs Stefan , Abdel-Mageed Asim B.
Published: April 2023

Additional detailed methods than can be incorporated in the body of the article
Supplementary figure 1, Supplementary figure 2,Supplementary figure 3,Supplementary figure 4 from Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care
Authors: El Messaoudi Safia , Mouliere Florent , Du Manoir Stanislas , Bascoul-Mollevi Caroline , Gillet Brigitte , Nouaille Michelle , Fiess Catherine , Crapez Evelyne , Bibeau Frederic , Theillet Charles , Mazard Thibault , Pezet Denis , Mathonnet Muriel , Ychou Marc , Thierry Alain R.
Published: April 2023

Supplementary figure 1: overall survival general data Supplementary figure 2: relation of ccfDNA parameters with clinical variables Supplementary figure 3: Kaplan Meier curves in mutant mCRC patients in function of mA with exclusion of the 5 BRAFV600E mutant patients. Supplementary figure 4:Kaplan Meier curves in mutant mCRC patients in function of mA% with exclusion of the 5 BRAFV600E mutant patients.
Supplementary figure legend from ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody–Drug Conjugate Treatment
Authors: Lamberts Laetitia E. , Menke-van der Houven van Oordt Catharina W. , ter Weele Eva J. , Bensch Frederike , Smeenk Michiel M. , Voortman Johannes , Hoekstra Otto S. , Williams Simon P. , Fine Bernard M. , Maslyar Daniel , de Jong Johan R. , Gietema Jourik A. , Schröder Carolien P. , Bongaerts Alphons H.H. , Lub-de Hooge Marjolijn N. , Verheul Henk M.W. , Sanabria Bohorquez Sandra M. , Glaudemans Andor W.J.M. , de Vries Elisabeth G.E.
Published: April 2023

Supplementary figure legend
Supplemental Figure 4 from Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA+ Liver Metastases
Authors: Katz Steven C. , Burga Rachel A. , McCormack Elise , Wang Li Juan , Mooring Wesley , Point Gary R. , Khare Pranay D. , Thorn Mitchell , Ma Qiangzhong , Stainken Brian F. , Assanah Earle O. , Davies Robin , Espat N. Joseph , Junghans Richard P.
Published: April 2023

Supplemental Figure 4. Cytokine response to treatment
Supplemental Figure 3 from Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA+ Liver Metastases
Authors: Katz Steven C. , Burga Rachel A. , McCormack Elise , Wang Li Juan , Mooring Wesley , Point Gary R. , Khare Pranay D. , Thorn Mitchell , Ma Qiangzhong , Stainken Brian F. , Assanah Earle O. , Davies Robin , Espat N. Joseph , Junghans Richard P.
Published: April 2023

Supplemental Figure 3. Radiographic studies
Supplementary Tables 1 - 15 from Genomic Alterations in the RB Pathway Indicate Prognostic Outcomes of Early-Stage Lung Adenocarcinoma
Authors: Choi Seongmin , Kim Hyeong Ryul , Sung Chang Ohk , Kim Jongkyu , Kim Sukjun , Ahn Sung-Min , Choi Chang-min , Chun Sung-Min , Choi Eun Kyung , Kim Sang-We , Kim Yong-Hee , Lee Ji-Young , Song Joon Seon , Kim Deokhoon , Haq Farhan , Lee Sun Young , Lee Jong-eun , Jung Wang-rim , Jang Hye Yoon , Yang Eunho , Lee Charles , Yu Eunsil , Kong Gu , Baek Daehyun , Jang Se Jin
Published: April 2023

Supplementary Tables 1 - 15. Supp. Table 1. Sequenced reads per tumor and normal sample. Supp. Table 2. Comparison of significantly mutated genes detected using various MuTect thresholds. Supp. Table 3. Comparison of the number and rate of substitutions between never-smokers and smokers. Supp. Table 4. Comparison of various methods used to compute the background mutation rate. Supp. Table 5. Significantly mutated genes detected in our discovery cohort. Supp. Table 6. Comparison of significantly mutated genes and previously reported cancer driver genes. Supp. Table 7. Thirteen significantly altered CNV regions detected in our discovery cohort. Supp. Table 8. Druggable target candidates in the 22 significantly mutated genes and the 60 genes in the significantly altered CNV regions detected in the discovery cohort. Supp. Table 9. Pathways significantly enriched in the 22 significantly mutated genes and the 60 genes included in the significantly altered CNV regions that were detected in the discovery cohort. Supp. Table 10. Cox multivariable regression analysis for RB pathway alterations. Supp. Table 11. Cox univariable regression analysis of RB pathway alterations. Supp. Table 12. Comparison of mutations detected using whole-exome sequencing and Sequenom in selected genes. Supp. Table 13. Prevalence of known driver candidates when using two different MuTect parameters. Supp. Table 14. Number of patients included in the overall, tumor, node, and metastasis stage categories. Supp. Table 15. List of potential cancer driver genes with somatic substitutions or small indels determined in previous studies.
Supplementary table S3 from A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer
Authors: Ma Cynthia X. , Luo Jingqin , Naughton Michael , Ademuyiwa Foluso , Suresh Rama , Griffith Malachi , Griffith Obi L. , Skidmore Zachary L. , Spies Nicholas C. , Ramu Avinash , Trani Lee , Pluard Timothy , Nagaraj Gayathri , Thomas Shana , Guo Zhanfang , Hoog Jeremy , Han Jing , Mardis Elaine , Lockhart Craig , Ellis Matthew J.
Published: April 2023

Supplementary Table S3. All observed coding mutations with detailed annotations
Supplementary Methods, Supplementary Figure Legends, and Supplementary Table Legends from Genomic Alterations in the RB Pathway Indicate Prognostic Outcomes of Early-Stage Lung Adenocarcinoma
Authors: Choi Seongmin , Kim Hyeong Ryul , Sung Chang Ohk , Kim Jongkyu , Kim Sukjun , Ahn Sung-Min , Choi Chang-min , Chun Sung-Min , Choi Eun Kyung , Kim Sang-We , Kim Yong-Hee , Lee Ji-Young , Song Joon Seon , Kim Deokhoon , Haq Farhan , Lee Sun Young , Lee Jong-eun , Jung Wang-rim , Jang Hye Yoon , Yang Eunho , Lee Charles , Yu Eunsil , Kong Gu , Baek Daehyun , Jang Se Jin
Published: April 2023

Supplementary Methods, Supplementary Figure Legends, and Supplementary Table Legends.
TIM-3 expression on lymphocytes from Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas
Authors: Kim Jennifer E. , Patel Mira A. , Mangraviti Antonella , Kim Eileen S. , Theodros Debebe , Velarde Esteban , Liu Ann , Sankey Eric W. , Tam Ada , Xu Haiying , Mathios Dimitrios , Jackson Christopher M. , Harris-Bookman Sarah , Garzon-Muvdi Tomas , Sheu Mary , Martin Allison M. , Tyler Betty M. , Tran Phuoc T. , Ye Xiaobu , Olivi Alessandro , Taube Janis M. , Burger Peter C. , Drake Charles G. , Brem Henry , Pardoll Drew M. , Lim Michael
Published: April 2023

Gating strategy to assess for surface expression of TIM-3 on (A) CD4+ and (B) CD8+ T cells isolated from peripheral lymph nodes, lungs, livers, spleens, and brains.
Supplementary Figure S1 from A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer
Authors: Ma Cynthia X. , Luo Jingqin , Naughton Michael , Ademuyiwa Foluso , Suresh Rama , Griffith Malachi , Griffith Obi L. , Skidmore Zachary L. , Spies Nicholas C. , Ramu Avinash , Trani Lee , Pluard Timothy , Nagaraj Gayathri , Thomas Shana , Guo Zhanfang , Hoog Jeremy , Han Jing , Mardis Elaine , Lockhart Craig , Ellis Matthew J.
Published: April 2023

Supplementary Fig. S1. Buparlisib dosing intensity by treatment cohorts
Supplemental Tables 1 and 2 from Hotspot Mutation Panel Testing Reveals Clonal Evolution in a Study of 265 Paired Primary and Metastatic Tumors
Authors: Goswami Rashmi S. , Patel Keyur P. , Singh Rajesh R. , Meric-Bernstam Funda , Kopetz E. Scott , Subbiah Vivek , Alvarez Ricardo H. , Davies Michael A. , Jabbar Kausar J. , Roy-Chowdhuri Sinchita , Lazar Alexander J. , Medeiros L. Jeffrey , Broaddus Russell R. , Luthra Rajyalakshmi , Routbort Mark J.
Published: April 2023

Supplemental Tables 1 and 2. Table 1. Germline single nucleotide polymorphism (SNP) concordance between matched primary/metastasis pairs. Table 2. Mutations seen in tumor/metastasis pairs with identical signatures (non-divergent) for the two most common cancers studied: breast and colon carcinoma.
Antibodies from Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas
Authors: Kim Jennifer E. , Patel Mira A. , Mangraviti Antonella , Kim Eileen S. , Theodros Debebe , Velarde Esteban , Liu Ann , Sankey Eric W. , Tam Ada , Xu Haiying , Mathios Dimitrios , Jackson Christopher M. , Harris-Bookman Sarah , Garzon-Muvdi Tomas , Sheu Mary , Martin Allison M. , Tyler Betty M. , Tran Phuoc T. , Ye Xiaobu , Olivi Alessandro , Taube Janis M. , Burger Peter C. , Drake Charles G. , Brem Henry , Pardoll Drew M. , Lim Michael
Published: April 2023

Antibodies used for flow cytometry (clones and dilutions)
Supplementary Figure S2 from CD47 Enhances In Vivo Functionality of Artificial Antigen-Presenting Cells
Authors: Bruns Heiko , Bessell Catherine , Varela Juan Carlos , Haupt Carl , Fang Jerry , Pasemann Shirin , Mackensen Andreas , Oelke Mathias , Schneck Jonathan P. , Schütz Christian
Published: April 2023

Supplementary Figure S2. Specificity and phenotype of MART1 and FluM1 specific CTL generated for 51Cr release assay.
Supplementary Tables 1-2 from Evaluation of a 5-Marker Blood Test for Colorectal Cancer Early Detection in a Colorectal Cancer Screening Setting
Authors: Werner Simone , Krause Friedemann , Rolny Vinzent , Strobl Matthias , Morgenstern David , Datz Christian , Chen Hongda , Brenner Hermann
Published: April 2023

S1: Study population characteristics of CT Study; S2: Sensitivities and specificities of the 5-marker blood test obtained in the CTStudy (Training Study).
Supplemental Figures 1-5 and Methods from Translational Impact of Nanoparticle–Drug Conjugate CRLX101 with or without Bevacizumab in Advanced Ovarian Cancer
Authors: Pham Elizabeth , Birrer Michael J. , Eliasof Scott , Garmey Edward G. , Lazarus Douglas , Lee Christina R. , Man Shan , Matulonis Ursula A. , Peters Christian G. , Xu Ping , Krasner Carolyn , Kerbel Robert S.
Published: April 2023

Supplemental Figures 1-5 and Methods. This file describes the change in HIF-1α, HIF-2α and downstream markers (Fig. S1), anti-tumor efficacy and change in HIF-1α when combining CRLX101 with Aflibercept (Fig. S2) or Pazopanib (Fig. S3), dose-dependent tumor efficacy and toxicity of CRLX101 in SCID mice (Fig. S4), and change in uptake of CRLX101 when administered with Bevacizumab (Fig. S5). Detailed methods describe immunohistochemistry, immunofluorescence and western blot analyses.
Supplementary Table 2 from c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer
Authors: Nebbioso Angela , Carafa Vincenzo , Conte Mariarosaria , Tambaro Francesco Paolo , Abbondanza Ciro , Martens Joost , Nees Matthias , Benedetti Rosaria , Pallavicini Isabella , Minucci Saverio , Garcia-Manero Guillermo , Iovino Francesco , Lania Gabriella , Ingenito Concetta , Belsito Petrizzi Valeria , Stunnenberg Hendrik G. , Altucci Lucia
Published: April 2023

Primer sequence, location and product of amplification size.
Supplemental Figure 4 from iNOS Expression in CD4+ T Cells Limits Treg Induction by Repressing TGFβ1: Combined iNOS Inhibition and Treg Depletion Unmask Endogenous Antitumor Immunity
Authors: Jayaraman Padmini , Alfarano Matthew G. , Svider Peter F. , Parikh Falguni , Lu Geming , Kidwai Sarah , Xiong Huabao , Sikora Andrew G.
Published: April 2023

Supplemental Figure 4. Human PBMC's were derived from healthy individuals and stained for CD4 and CD45RO antibodies after which CD4+CD45RO- cells were sorted out and used to generate T-regs ex vivo in the presence or absence of TGF-ÃŽÂ²1 and L-NIL.
Supplementary Figure 7 from c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer
Authors: Nebbioso Angela , Carafa Vincenzo , Conte Mariarosaria , Tambaro Francesco Paolo , Abbondanza Ciro , Martens Joost , Nees Matthias , Benedetti Rosaria , Pallavicini Isabella , Minucci Saverio , Garcia-Manero Guillermo , Iovino Francesco , Lania Gabriella , Ingenito Concetta , Belsito Petrizzi Valeria , Stunnenberg Hendrik G. , Altucci Lucia
Published: April 2023

SAHA effects in different cell lines.
Supplemental Figure 3.1 from iNOS Expression in CD4+ T Cells Limits Treg Induction by Repressing TGFβ1: Combined iNOS Inhibition and Treg Depletion Unmask Endogenous Antitumor Immunity
Authors: Jayaraman Padmini , Alfarano Matthew G. , Svider Peter F. , Parikh Falguni , Lu Geming , Kidwai Sarah , Xiong Huabao , Sikora Andrew G.
Published: April 2023

Supplemental Figure 3.1. Splenocytes ( CFSE labelled) from naÃƒÂ¯ve WT mice were activated with soluble anti-CD3 and anti-CD28 antibodies in the presence of RFP+Treg cells sorted (as mentioned above) from control, LNIL and TGF-ÃŽÂ² groups. After 72 hours, cells were havested and surface stained for CD4 T cells and CFSE dilution profile was measured by flow cytometry.
Supplementary Figure 4 from c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer
Authors: Nebbioso Angela , Carafa Vincenzo , Conte Mariarosaria , Tambaro Francesco Paolo , Abbondanza Ciro , Martens Joost , Nees Matthias , Benedetti Rosaria , Pallavicini Isabella , Minucci Saverio , Garcia-Manero Guillermo , Iovino Francesco , Lania Gabriella , Ingenito Concetta , Belsito Petrizzi Valeria , Stunnenberg Hendrik G. , Altucci Lucia
Published: April 2023

Epigenetic status of the TRAIL promoter region after HDACi exposure.
Supplementary Figure 3 from c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer
Authors: Nebbioso Angela , Carafa Vincenzo , Conte Mariarosaria , Tambaro Francesco Paolo , Abbondanza Ciro , Martens Joost , Nees Matthias , Benedetti Rosaria , Pallavicini Isabella , Minucci Saverio , Garcia-Manero Guillermo , Iovino Francesco , Lania Gabriella , Ingenito Concetta , Belsito Petrizzi Valeria , Stunnenberg Hendrik G. , Altucci Lucia
Published: April 2023

c-Myc down-regulation modulates DR5 and p21 genes.
Suppl. Methods from c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer
Authors: Nebbioso Angela , Carafa Vincenzo , Conte Mariarosaria , Tambaro Francesco Paolo , Abbondanza Ciro , Martens Joost , Nees Matthias , Benedetti Rosaria , Pallavicini Isabella , Minucci Saverio , Garcia-Manero Guillermo , Iovino Francesco , Lania Gabriella , Ingenito Concetta , Belsito Petrizzi Valeria , Stunnenberg Hendrik G. , Altucci Lucia
Published: April 2023

Suppl. Methods
AVPC Molecular Signature Supplementary Tables 1-10 from Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers
Authors: Aparicio Ana M. , Shen Li , Tapia Elsa Li Ning , Lu Jing-Fang , Chen Hsiang-Chun , Zhang Jiexin , Wu Guanglin , Wang Xuemei , Troncoso Patricia , Corn Paul , Thompson Timothy C. , Broom Bradley , Baggerly Keith , Maity Sankar N. , Logothetis Christopher J.
Published: April 2023

SUPPLEMENTARY TABLE 1. AVPC ('ANAPLASTIC') ELIGIBILITY CRITERIA FOR NCT00514540, A PHASE II STUDY OF CARBOPLATIN AND DOCETAXEL IN PATIENTS WITH ANAPLASTIC PROSTATE CARCINOMA. SUPPLEMENTARY TABLE 2. CLINICOPATHOLOGICAL FEATURES OF THE PDX DONOR PATIENTS. SUPPLEMENTARY TABLE 3. PDX GROWTH RATE AND PSA PRODUCTION. SUPPLEMENTARY TABLE 4. ANTIBODIES USED FOR IMMUNOHISTOCHEMISTRY AND WESTERN BLOT. SUPPLEMENTARY TABLE 5. qRT-PCR PRIMER SEQUENCES. SUPPLEMENTARY TABLE 6. DONOR PATIENT CHARACTERISTICS. SUPPLEMENTARY TABLE 7. SERUM MARKER LEVELS AT TIME OF REGISTRATION TO NCT00514540. SUPPLEMENTARY TABLE 8. PRINCIPAL COMPONENT VARIATE WEIGHTINGS TCGA/UNSELECTED CRPC/AVPC SAMPLES. SUPPLEMENTARY TABLE 9. LINEAR DISCRIMINANT ANALYSIS WEIGHTS. SUPPLEMENTARY TABLE 10. Tp53 MUTATIONS DETECTED IN TCGA, UNSELECTED CRPC (21) AND AVPC SAMPLES.
Supplemental Tables 1-6 from Tumor-Associated Macrophages in SHH Subgroup of Medulloblastomas
Authors: Margol Ashley S. , Robison Nathan J. , Gnanachandran Janahan , Hung Long T. , Kennedy Rebekah J. , Vali Marzieh , Dhall Girish , Finlay Jonathan L. , Erdreich-Epstein Anat , Krieger Mark D. , Drissi Rachid , Fouladi Maryam , Gilles Floyd H. , Judkins Alexander R. , Sposto Richard , Asgharzadeh Shahab
Published: April 2023

Supplemental Tables 1-6 Supplemental Table 1. Patient and tumor characteristics Supplemental Table 2. TLDA design (45 genes) Supplemental Table 3. Information for samples evaluated using HuE Supplemental Table 4. TLDA 31-gene molecular classification of core samples Supplemental Table 5. TLDA 31-gene classification for samples without HuEx data Supplemental Table 6. TLDA 31-gene Confusion Matrix
Supplementary Figure 4 from Secreted Frizzled-Related Protein 3 (SFRP3) Is Required for Tumorigenesis of PAX3–FOXO1-Positive Alveolar Rhabdomyosarcoma
Authors: Kephart Julie J.G. , Tiller Rosanne G.J. , Crose Lisa E.S. , Slemmons Katherine K. , Chen Po-Han , Hinson Ashley R. , Bentley Rex C. , Chi Jen-Tsan Ashley , Linardic Corinne M.
Published: April 2023

Supplementary Figure 4. Doxycycline does not interfere with the anti-tumor effect of vincristine.
Supplementary Figure 3 from Secreted Frizzled-Related Protein 3 (SFRP3) Is Required for Tumorigenesis of PAX3–FOXO1-Positive Alveolar Rhabdomyosarcoma
Authors: Kephart Julie J.G. , Tiller Rosanne G.J. , Crose Lisa E.S. , Slemmons Katherine K. , Chen Po-Han , Hinson Ashley R. , Bentley Rex C. , Chi Jen-Tsan Ashley , Linardic Corinne M.
Published: April 2023

Supplementary Figure 3. Shorter duration of SFRP3 suppression inhibits tumor growth in vivo.
Supplementary Table 2 from PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor–Treated Melanoma Patients
Authors: Kakavand Hojabr , Wilmott James S. , Menzies Alexander M. , Vilain Ricardo , Haydu Lauren E. , Yearley Jennifer H. , Thompson John F. , Kefford Richard F. , Hersey Peter , Long Georgina V. , Scolyer Richard A.
Published: April 2023

Supplementary Table 2. The percentage of PD-L1 expressing tumor/immune cells and the intensity of staining in these samples used to derive the immuno-reactive score (IRS) for the 40 patients. *Immune cells= lymphocytes and macrophages.
Supplementary Figure 4 from HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients
Authors: Napolitano Andrea , Antoine Daniel J. , Pellegrini Laura , Baumann Francine , Pagano Ian , Pastorino Sandra , Goparaju Chandra M. , Prokrym Kirill , Canino Claudia , Pass Harvey I. , Carbone Michele , Yang Haining
Published: April 2023

No correlation between levels of total or hyper-acetylated HMGB1 and other markers
supplemental figure legend from Genomic Analysis of Metastatic Cutaneous Squamous Cell Carcinoma
Authors: Li Yvonne Y. , Hanna Glenn J. , Laga Alvaro C. , Haddad Robert I. , Lorch Jochen H. , Hammerman Peter S.
Published: April 2023

supplemental figure legend
Supplementary Figure 3 from HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients
Authors: Napolitano Andrea , Antoine Daniel J. , Pellegrini Laura , Baumann Francine , Pagano Ian , Pastorino Sandra , Goparaju Chandra M. , Prokrym Kirill , Canino Claudia , Pass Harvey I. , Carbone Michele , Yang Haining
Published: April 2023

Other ROC curves of total and hyper-acetylated HMGB1
Supplementary Table 1 from Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial
Authors: Jovelet Cécile , Ileana Ecaterina , Le Deley Marie-Cécile , Motté Nelly , Rosellini Silvia , Romero Alfredo , Lefebvre Celine , Pedrero Marion , Pata-Merci Noémie , Droin Nathalie , Deloger Marc , Massard Christophe , Hollebecque Antoine , Ferté Charles , Boichard Amélie , Postel-Vinay Sophie , Ngo-Camus Maud , De Baere Thierry , Vielh Philippe , Scoazec Jean-Yves , Vassal Gilles , Eggermont Alexander , André Fabrice , Soria Jean-Charles , Lacroix Ludovic
Published: April 2023

mutations' allele frequencies in tDNA and cfDNA
Supplementary Figure S7 from Activation of Vitamin D Receptor Signaling Downregulates the Expression of Nuclear FOXM1 Protein and Suppresses Pancreatic Cancer Cell Stemness
Authors: Li Zhiwei , Jia Zhiliang , Gao Yong , Xie Dacheng , Wei Daoyan , Cui Jiujie , Mishra Lopa , Huang Suyun , Zhang Yanqiao , Xie Keping
Published: April 2023

Supplementary Figure S7. Impact of altered VDR signaling on PDAC stem cell biology
Supplementary Figure S4 from Activation of Vitamin D Receptor Signaling Downregulates the Expression of Nuclear FOXM1 Protein and Suppresses Pancreatic Cancer Cell Stemness
Authors: Li Zhiwei , Jia Zhiliang , Gao Yong , Xie Dacheng , Wei Daoyan , Cui Jiujie , Mishra Lopa , Huang Suyun , Zhang Yanqiao , Xie Keping
Published: April 2023

Supplementary Figure S4. Impact of altered VDR signaling on the growth of various PDAC cell lines in vitro
Supplementary Figure 3 from Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma
Authors: Di Stefano Anna Luisa , Fucci Alessandra , Frattini Veronique , Labussiere Marianne , Mokhtari Karima , Zoppoli Pietro , Marie Yannick , Bruno Aurelie , Boisselier Blandine , Giry Marine , Savatovsky Julien , Touat Mehdi , Belaid Hayat , Kamoun Aurelie , Idbaih Ahmed , Houillier Caroline , Luo Feng R. , Soria Jean-Charles , Tabernero Josep , Eoli Marica , Paterra Rosina , Yip Stephen , Petrecca Kevin , Chan Jennifer A. , Finocchiaro Gaetano , Lasorella Anna , Sanson Marc , Iavarone Antonio
Published: April 2023

Supplementary Figure 3. Evaluation of the expression of FGFR3-TACC3 fusion elements.
Supplementary Figure 2 from Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma
Authors: Di Stefano Anna Luisa , Fucci Alessandra , Frattini Veronique , Labussiere Marianne , Mokhtari Karima , Zoppoli Pietro , Marie Yannick , Bruno Aurelie , Boisselier Blandine , Giry Marine , Savatovsky Julien , Touat Mehdi , Belaid Hayat , Kamoun Aurelie , Idbaih Ahmed , Houillier Caroline , Luo Feng R. , Soria Jean-Charles , Tabernero Josep , Eoli Marica , Paterra Rosina , Yip Stephen , Petrecca Kevin , Chan Jennifer A. , Finocchiaro Gaetano , Lasorella Anna , Sanson Marc , Iavarone Antonio
Published: April 2023

Supplementary Figure 2. Schematics of FGFR3-TACC3 genomic breakpoints.
Supplementary table 2 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
Authors: van Gool Inge C. , Eggink Florine A. , Freeman-Mills Luke , Stelloo Ellen , Marchi Emanuele , de Bruyn Marco , Palles Claire , Nout Remi A. , de Kroon Cor D. , Osse Elisabeth M. , Klenerman Paul , Creutzberg Carien L. , Tomlinson Ian P.M. , Smit Vincent T.H.B.M. , Nijman Hans W. , Bosse Tjalling , Church David N.
Published: April 2023

Supplementary table 2. Antigen presentation pathway mutations in TCGA POLE proofreading-mutant ECs
Supplementary figure 4 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
Authors: van Gool Inge C. , Eggink Florine A. , Freeman-Mills Luke , Stelloo Ellen , Marchi Emanuele , de Bruyn Marco , Palles Claire , Nout Remi A. , de Kroon Cor D. , Osse Elisabeth M. , Klenerman Paul , Creutzberg Carien L. , Tomlinson Ian P.M. , Smit Vincent T.H.B.M. , Nijman Hans W. , Bosse Tjalling , Church David N.
Published: April 2023

Supplementary figure 4. CD20+ and FOXP3+ tumor infiltrate according to EC molecular subtype
Supplementary figure 2 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
Authors: van Gool Inge C. , Eggink Florine A. , Freeman-Mills Luke , Stelloo Ellen , Marchi Emanuele , de Bruyn Marco , Palles Claire , Nout Remi A. , de Kroon Cor D. , Osse Elisabeth M. , Klenerman Paul , Creutzberg Carien L. , Tomlinson Ian P.M. , Smit Vincent T.H.B.M. , Nijman Hans W. , Bosse Tjalling , Church David N.
Published: April 2023

Supplementary figure 2. CD3+ tumor infiltrate according to EC molecular subtype
Supplemental Figures from RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
Authors: Loi Sherene , Dushyanthen Sathana , Beavis Paul A. , Salgado Roberto , Denkert Carsten , Savas Peter , Combs Susan , Rimm David L. , Giltnane Jennifer M. , Estrada Monica V. , Sánchez Violeta , Sanders Melinda E. , Cook Rebecca S. , Pilkinton Mark A. , Mallal Simon A. , Wang Kai , Miller Vincent A. , Stephens Phil J. , Yelensky Roman , Doimi Franco D. , Gómez Henry , Ryzhov Sergey V. , Darcy Phillip K. , Arteaga Carlos L. , Balko Justin M.
Published: April 2023

Supplemental Figure 1: No clear interaction of molecular subtype with change in TIL score dureing NAC. Supplemental Figure 2: No clear relationship between pre-NAC TILs or change in TILs with RFS or OS. Supplemental Figure 3: No clear association between pre-NAC or post-NAC TILs and total number of targeted alterations identified by targeted NGS. Supplemental Figure 4: A) Percent of high expressers of PD-L1 (>1 standard deviation from the mean) in each molecular subtype in the TCGA breast cancer dataset. Supplemental Figure 5: MEK inhibition down-regulates downstream ERK signalling and inhibits proliferation of TNBC murine breast cancer lines AT3ova and 4T1.9 in vitro. Supplemental Figure 6: Efficacy of selumetinib and anti-PD-L1 therapy in MMTV-Neu models. Supplemental Figure 7: Pharmacodynamic activity of trametinib and selumetinib in vivo.
Supplementary Table 1 from Trabectedin Efficacy in Ewing Sarcoma Is Greatly Increased by Combination with Anti-IGF Signaling Agents
Authors: Amaral Ana Teresa , Garofalo Cecilia , Frapolli Roberta , Manara Maria Cristina , Mancarella Caterina , Uboldi Sarah , Giandomenico Silvana Di , Ordóñez Jose Luis , Sevillano Victoria , Malaguarnera Roberta , Picci Piero , Hassan A. Bass , Alava Enrique De , D'Incalci Maurizio , Scotlandi Katia
Published: April 2023

Supplementary Table 1. Primers sequences
Appendix A from Treatment Planning and Fracture Prediction in Patients with Skeletal Metastasis with CT-Based Rigidity Analysis
Authors: Nazarian Ara , Entezari Vahid , Zurakowski David , Calderon Nathan , Hipp John A. , Villa-Camacho Juan C. , Lin Patrick P. , Cheung Felix H. , Aboulafia Albert J. , Turcotte Robert , Anderson Megan E. , Gebhardt Mark C. , Cheng Edward Y. , Terek Richard M. , Yaszemski Michael , Damron Timothy A. , Snyder Brian D.
Published: April 2023

Appendix A. Calculation of Structural Rigidity
Supplementary Table S4 from LOXL2 Is Highly Expressed in Cancer-Associated Fibroblasts and Associates to Poor Colon Cancer Survival
Authors: Torres Sofía , Garcia-Palmero Irene , Herrera Mercedes , Bartolomé Rubén A. , Peña Cristina , Fernandez-Aceñero M. Jesús , Padilla Guillermo , Peláez-García Alberto , Lopez-Lucendo María , Rodriguez-Merlo Rufo , de Herreros Antonio García , Bonilla Félix , Casal J. Ignacio
Published: April 2023

Supplementary Table S4. Genomatix Analysis of the predicted important biological functions
Supplmentary Methods, Tables 1 - 6, Figure Legends from The Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer
Authors: Fang Fang , Munck Joanne , Tang Jessica , Taverna Pietro , Wang Yinu , Miller David F.B. , Pilrose Jay , Choy Gavin , Azab Mohammad , Pawelczak Katherine S. , VanderVere-Carozza Pamela , Wagner Michael , Lyons John , Matei Daniela , Turchi John J. , Nephew Kenneth P.
Published: April 2023

Supplementary methods Supplementary Tables S1-S6 Supplementary Figure legends for SF1-SF11 Supplementary Table S1. Primers used for qRT-PCR Supplementary Table S2. Primers used for pyrosequencing Supplementary Table S3. IC50 values for CDDP resensitization by SGI-110 and 5-aza-dC in vitro Supplementary Table S4. Relative induction of MLH1 mRNA levels in response to SGI-110 Supplementary Table S5. Candidate drivers of OC CDDP Resistance Supplementary Table S6. Relative induction of ZIC1 mRNA levels in response to SGI-110
Supplementary Table S4. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus
Authors: Jenkinson Claire , Elliott Victoria L. , Evans Anthony , Oldfield Lucy , Jenkins Rosalind E. , O'Brien Darragh P. , Apostolidou Sophia , Gentry-Maharaj Aleksandra , Fourkala Evangelia-O , Jacobs Ian J. , Menon Usha , Cox Trevor , Campbell Fiona , Pereira Stephen P. , Tuveson David A. , Park B. Kevin , Greenhalf William , Sutton Robert , Timms John F. , Neoptolemos John P. , Costello Eithne
Published: April 2023

Comparison of TSP-1 serum levels in PDAC patients with clinicopathological parameters.